Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target.

@article{Costello2004PerfusionO9,
  title={Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target.},
  author={Brendan Costello and Chenggang Li and Sarah Emily Duff and David N. Butterworth and Ali Khan and Michael Shane Perkins and Susan Costen Owens and Abdul Fattah Al-Mowallad and Sarah O'Dwyer and Shant Kumar},
  journal={International journal of cancer},
  year={2004},
  volume={109 3},
  pages={
          436-41
        }
}
There is strong published and unpublished evidence that our CD105 Mab E9, which is highly reactive with angiogenic endothelial cells, could be a useful reagent to target the vasculature of solid tumors in man. Since Mab E9 does not cross-react with animal tissues, we undertook here to evaluate its localization using human kidney as an ex vivo model. Perfusion was performed through the renal artery of 99Tcm-labeled purified CD105 Mab in freshly excised kidneys from 7 patients with renal… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Similar Papers

Loading similar papers…